Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Stephen A. Harrison(Pinnacle Clinical Research), M. Scott Harris(Altimmune (United States)), Sarah Browne(National Institute of Allergy and Infectious Diseases), Julio Gutiérrez(Scripps Institution of Oceanography), John J. Suschak(United States Army Medical Research Institute of Infectious Diseases), Jay Yang(Wayne State University), M. Scot Roberts(Altimmune (United States)), Shaheen Tomah(Altimmune (United States))
Cited by 135
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789